Considerations for using potential surrogate endpoints in cancer screening trials.
Webb AB, Berg CD, Castle PE, Crosby D, Etzioni R, Kessler LG, Menon U, Parmar M, Steele RJC, Sasieni PD.
Webb AB, et al. Among authors: steele rjc.
Lancet Oncol. 2024 May;25(5):e183-e192. doi: 10.1016/S1470-2045(24)00015-9.
Lancet Oncol. 2024.
PMID: 38697164
Free PMC article.
Review.